Syntekabio extracts thousands of blood from various ethnic groups of the world, performs NGS sequencing and performs genomic analysis with MAHA supercomputer. The data analyzed in this way is created with three DBs, allele depth, genotype, and haplotype by Adiscan engine which is Syntekabio’s own technology.
These three DBs are stored as "MAHA-FsDx", a high-speed parallel distributed storage for big data, and are completed with genome integration data. The technology to create and operate these big data is called the genome map platform technology.
*What’s ADISCAN engine? It is Syntekabio’s own technology which is a bio-software that extracts the entire length of a person's entire genome into a single long string.
Due to the recent rapid development of the biotechnology industry, the demand for genetic testing has increased, and a MAHA supercomputer dedicated to genetic testing has been developed to handle complex genome analysis more accurately and quickly.
Thus, the MAHA-FsDx for genome-specific system (MAHA-FsDx) lowers the data processing cost and enables genome-based disease diagnostics to operate in optimal environments.
After NGS testing, It is utilized in various aspects of genomic analysis such as reducing the false positives by utilizing big data of genome based on MAHA Supercom system. In addition, the MAHA-FsDx for genome-specific applications consists of a memory-cache-based distributed parallel computing environment for genome-specific memory and it is designed for faster analysis of whole-genome and integration of it.
A feature of the MAHAh-SuperCom system is the supercomputing system that maximizes the analysis of large-scale whole-genome. The system includes a number of ETRI technology patents, and the ETRI developed MAHA system “MAHA-FsD“ by optimizing the memory cache storage server, data chunk size and network environment to further increase I / O.
This technology "MAHA-FsDx" has its own patent application.
Recently, the performance of GPGPU (general purpose graphic process unit) has been innovating from 500 cores to 10,000 cores and 30,000 cores (Volta architecture)
Thanks to the development of these high performance computing hardware systems, a variety of molecular modeling and simulation techniques have been making advances and usability improved. In a GPU-based computing environment, the technology to simulate drug-target protein interactions has accelerated nearly 10 times and the accuracy of predictions is also improving. According to this trend, In silico modeling technology, drug interaction with normal / mutated proteins, and simulation technology for predicting drug efficacy are attracting attention as new technologies maximizing the efficiency of new drug development.
The BioMap system, molecular dynamics simulation system, and drug virtual search system are in silico analysis infrastructure to support successful clinical trials of new drug candidates. Syntekabio provides in silico service that can support the development of drug candidates, validation of candidate drug efficacy and toxicity, and clinical trial design by the supercomputer-based genome integrated analysis system.
Hyplotying-panel is composed of HLA gene (tissue suitability test), KIR (killer cell immuniglobulin-like receptor), drug metabolic gene, and  blood gene. In particular, Since the genes used are highly polymorphic, it is difficult to calculate genetic information and genotypes.
Syntekabio has successfully applied for a patent for the algorithm that calculates the genotype based on the recently developed HLA typing technology, ie stratification technology.
Especially, HLA gene (tissue suitability test) and KIR utilization is as follows.
When transplanting tissues between different individuals in all higher animals, the immune system of the recipient is aware of the tissue of the donor and causes a rejection. Therefore, patients and donors who need tissue transplantation should perform histocompatibility. HLA types of patient and donor should b similar or matched to minimized rejection and increase transplant success. With Syntekabio’s Big data driven program and by accurately predicting HLA types, you can not only identify the tissue fitness required for organ transplants, but also provide information related to person identification and disease susceptibility.
Drug metabolic gene and blood gene is utilized as follows.
Humans are always exposed to numerous foods, nutrients, and drugs. Most of the drugs used for the treatment and prevention of diseases are xenobiotics which are not present in human body. When a substance that our body has never experienced has come into the body, we will try to send them out of the body. Metabolism is one of the most aggressive human activities that send drugs, which are exogenous, out of the body. Recent studies have shown that optimal drugs and dosages can be predicted using different genotypes for each individual.
As human nucleotide sequences are decoded and the function of some genes is revealed, several genotypes related to the response have been found to be closely related to the development of drug efficacy or the occurrence of adverse events.
Organ transplantation, drug metabolism, cord blood transplantation, bone marrow transplantation, stem cell treatment and etc: performed in order to select appropriate donors
Assistive methods for disease diagnosis: Ankylosing spondylitis, rheumatoid arthritis, psoriasis, etc., which are closely related to specific HLA types
Forensic medicine: personal identification like parent identification and criminal identification
Other genetic related studies, immunological studies, inferred data from gene analysis, etc.